Ivy Leaf Extract

Hedera helix
Evidence Level
Limited
3 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Ivy leaf extract is the best-selling herbal cough preparation in Europe, where standardized dry extracts are licensed for cough with phlegm and catarrh of the airways. Its triterpene saponins, mainly hederacoside C and its active metabolite alpha-hederin, are thought to thin mucus and keep beta-2 receptors available on airway muscle. Dozens of studies exist, but a 2021 systematic review found nearly all of them uncontrolled or open-label, with very few placebo comparisons, and concluded the data do not yet establish that ivy leaf relieves cough better than placebo. Tolerability is consistently good, which is much of why it remains so widely used.

Studied Dose Standardized dry leaf extract, about 35 mg three times daily as syrup or drops
Active Compound Triterpene saponins: hederacoside C and alpha-hederin

Benefits

Expectorant support for a productive cough

Ivy leaf saponins are classed as secretolytic, meaning they thin airway mucus so it clears more easily. European regulators license it for cough with phlegm. Trials that measured cough objectively rather than by questionnaire are scarce, so the size of the effect is not well pinned down.

Eases bronchitis symptoms in practice studies

Large post-marketing studies in people with acute bronchitis report cough, sputum and chest tightness improving over roughly a week. These studies had no placebo group, and most acute coughs resolve on their own in that time, so they document what happens on the syrup rather than what the syrup adds.

Airway smooth muscle relaxation in asthma research

Small trials in children with mild persistent asthma found modest changes in some spirometry measures alongside usual care. This work is early and ivy leaf is not a controller medication, so no one should reduce an inhaler because of it.

Well tolerated in children with respiratory illness

The pediatric safety record is the strongest part of the file. Across thousands of children in practice studies and controlled use, adverse events were uncommon and mostly digestive. That tolerability, plus sugar-free syrup formats, explains much of its place in European pediatrics.

Mechanism of action

1

Secretolytic action on airway mucus

Triterpene saponins lower the surface tension of airway secretions and stimulate submucosal glands through a vagal reflex arising in the stomach lining, which makes mucus thinner and easier to move.

2

Beta-2 receptor preservation

Alpha-hederin appears to block internalization of beta-2 adrenergic receptors on airway smooth muscle and alveolar cells, leaving more receptors on the surface. The result is greater adrenaline-driven bronchial relaxation and more surfactant release.

3

Hederacoside C as a prodrug

Hederacoside C, the most abundant saponin in the leaf, is largely inactive until gut and liver enzymes strip its sugars to release alpha-hederin, the compound responsible for the receptor effect.

4

Anti-inflammatory and antimicrobial activity

Ivy saponins damp inflammatory signaling in cultured airway cells and show modest activity against some bacteria and fungi in the laboratory. Neither effect has been shown to matter at the doses people actually swallow.

Clinical trials

1
Updated Systematic Review - Ivy Leaf for Acute URTI
PubMed

Systematic review updating an earlier 2011 review of ivy leaf preparations in acute upper respiratory tract infection (Sierocinski E, Holzinger F, Chenot JF 2021, Eur J Clin Pharmacol 77(8):1113-1122, PMID 33523253).

Adults and children with acute upper respiratory tract infection or cough.

The reviewers found many published studies but very few with a control group, and rated overall methodological quality as poor. They concluded the available data do not allow a firm statement that ivy leaf preparations relieve cough better than placebo, while noting that the preparations were consistently well tolerated.

2
Earlier Systematic Review of Ivy Leaf Trials
PubMed

Systematic review of clinical trials of ivy leaf for acute upper respiratory tract infections (Holzinger F, Chenot JF 2011, Evid Based Complement Alternat Med 2011:382789, PMID 20976077).

Trials of ivy leaf mono-preparations in acute upper respiratory infection.

The 2011 review identified ten studies and reported that most were uncontrolled post-marketing surveillance rather than randomized comparisons. It concluded there was some evidence of effectiveness for improving respiratory function in children with chronic bronchial asthma, but no convincing evidence for cough in acute infection. The 2021 update reached the same conclusion.

3
Review of Ivy Dry Extract in Productive Cough
PubMed

Review of the efficacy of dry ivy leaf extract in productive cough (Schonknecht K, Fal AM, Mastalerz-Migas A, Joachimiak M, Doniec Z 2017, Wiad Lek 70(6):1026-1033, PMID 29478973).

Adults and children treated for productive cough with standardized ivy dry extract.

The authors summarize the European regulatory position and the practice-study data supporting ivy dry extract as a secretolytic for productive cough, and report a favorable tolerability profile. It is a narrative review rather than a meta-analysis, so it inherits the quality limits of the studies it covers.

Side effects and drug interactions

Common Potential side effects

Nausea, stomach ache and diarrhea are the most frequently reported effects and are usually mild.
Allergic reactions, including rash and urticaria, occur occasionally.
Alcohol-containing drop formulations are unsuitable for young children and for people avoiding alcohol.
Very large amounts of the raw plant are irritant; only standardized extracts should be taken.
A cough that lasts beyond about three weeks, or comes with fever or blood, needs medical assessment rather than a cough syrup.

Important Drug interactions

Cough suppressants such as dextromethorphan or codeine: pairing a mucus-thinner with a cough blocker can trap secretions.
Inhaled beta-2 agonists: the saponins act on the same receptor system, though no clinical interaction has been documented.
Alcohol-sensitizing drugs such as disulfiram or metronidazole: relevant only to alcohol-based drop formulations.
No clinically significant cytochrome P450 interactions have been reported for standardized ivy extracts.

Frequently asked questions about Ivy Leaf Extract

What is Ivy Leaf Extract?

Ivy leaf extract is the best-selling herbal cough preparation in Europe, where standardized dry extracts are licensed for cough with phlegm and catarrh of the airways.

What is Ivy Leaf Extract used for?

Ivy Leaf Extract is researched primarily for Respiratory Health. Ivy leaf saponins are classed as secretolytic, meaning they thin airway mucus so it clears more easily. European regulators license it for cough with phlegm.

What is the recommended dosage of Ivy Leaf Extract?

The clinically studied dose is Standardized dry leaf extract, about 35 mg three times daily as syrup or drops Always follow the product label and check with a healthcare provider for personal advice.

Is Ivy Leaf Extract safe, and does it have side effects?

For most healthy adults, Ivy Leaf Extract is well tolerated at studied doses. Reported effects can include: Nausea, stomach ache and diarrhea are the most frequently reported effects and are usually mild. Allergic reactions, including rash and urticaria, occur occasionally. It may also interact with some medications. Ivy Leaf Extract is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Ivy Leaf Extract interact with any medications?

Possible interactions include: Cough suppressants such as dextromethorphan or codeine: pairing a mucus-thinner with a cough blocker can trap secretions. Inhaled beta-2 agonists: the saponins act on the same receptor system, though no clinical interaction has been documented. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Ivy Leaf Extract?

NutraSmarts rates the evidence for Ivy Leaf Extract as Limited (2 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sierocinski E, Holzinger F, Chenot JF. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review. Eur J Clin Pharmacol. 2021;77(8):1113-1122..PubMedUsed to support: The key evidence statement on this page: most published ivy leaf studies lack a control group and are of poor methodological quality, so the data do not establish a cough benefit over placebo, though tolerability is good.
  2. Holzinger F, Chenot JF. Systematic review of clinical trials assessing the effectiveness of ivy leaf (hedera helix) for acute upper respiratory tract infections. Evid Based Complement Alternat Med. 2011;2011:382789..PubMedUsed to support: The original systematic review, cited for the finding that most of the literature is uncontrolled post-marketing surveillance and for the limited asthma spirometry signal in children.
  3. Baharara H, Moghadam AT, Sahebkar A, Emami SA, Tayebi T, Mohammadpour AH. The Effects of Ivy (Hedera helix) on Respiratory Problems and Cough in Humans: A Review. Adv Exp Med Biol. 2021;1328:361-376..PubMedUsed to support: A review of the human respiratory literature on ivy, supporting the description of its secretolytic use and its generally favorable safety record.
  4. Schonknecht K, Fal AM, Mastalerz-Migas A, Joachimiak M, Doniec Z. Efficacy of dry extract of ivy leaves in the treatment of productive cough. Wiad Lek. 2017;70(6):1026-1033..PubMedUsed to support: Used for the European regulatory framing of standardized ivy dry extract as a secretolytic for productive cough and for the reported tolerability profile.